SOLID TUMORS

This early-stage trial tests a new type of drug that can both find and treat cancer that has spread to the brain. The study includes 10 adults with solid tumors, specifically HER2-positive breast cancer, that have active brain metastases. The goal is to see if the drug can target…

This early-stage study tests a personalized cell therapy for people with advanced small cell lung cancer or similar neuroendocrine tumors that have stopped responding to standard treatment. Researchers take a patient's own immune cells, modify them in the lab to recognize a prote…

This early-stage trial tests the safety of a new drug called ATB-320 in 24 adults with advanced solid tumors that have spread or stopped responding to standard treatments. The main goal is to find the highest safe dose and identify any side effects. Participants will receive the …

This study tests whether combining lenvatinib (a daily pill) with a PD-1 inhibitor (an immunotherapy given by IV every 3 weeks) can shrink or stop advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers (like esop…

This study is for people with advanced solid tumors (like lung or colorectal cancer) who have already been helped by the drug adagrasib in a previous trial. It allows them to keep receiving the treatment and monitors any side effects. The goal is to provide continued care and gat…

This study tests an experimental drug, BMS-986504, in people with advanced solid tumors that have a missing MTAP gene. The drug is given alone or with other cancer treatments. The goal is to see if it can shrink tumors and to check for side effects. About 260 adults with various …

This early-phase study tests a new type of cell therapy for people with certain cancers (lymphoma, myeloma, and solid tumors like kidney cancer and sarcoma) that have returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are modified …

This early-stage study tests a new drug called QLS5316 in about 300 people with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 326 adults aged 18 to 75 with good overall health may join.

This study tests a drug called romiplostim N01 in 60 adults with solid tumors (like lung or breast cancer) who have low platelets from radiation-based treatments. The goal is to see if it safely raises platelet counts within 2 weeks, reducing the need for transfusions. It is a ph…

This early-phase study tests a new drug, BI 1831169, combined with an existing cancer immunotherapy (anti-PD1 antibody) in Japanese adults with advanced solid tumors that have spread or no longer respond to standard treatments. The main goal is to find the highest safe dose of th…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find the safest dose and check …

This study tests a new radioactive imaging agent called 68Ga-B6FA-01, designed to make PET/CT scans more accurate for detecting and staging solid tumors. The probe targets two different markers found on cancer cells and their surroundings, which may provide clearer images than cu…